Healthcare provider profile · identity verified

Christopher Franklin Vaughns, M.D.

Internal Medicine · DEARBORN, MI · NPI 1861757205

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	569	171
Amlodipine Besylate	Amlodipine Besylate	375	116
Lisinopril	Lisinopril	312	96
Losartan Potassium	Losartan Potassium	251	74
Metformin Hcl	Metformin Hcl	216	74
Metoprolol Succinate	Metoprolol Succinate	207	62
Nifedipine Er	Nifedipine	200	51
Simvastatin	Simvastatin	174	47
Omeprazole	Omeprazole	163	60
Rosuvastatin Calcium	Rosuvastatin Calcium	150	42
Levothyroxine Sodium	Levothyroxine Sodium	133	43
Eliquis	Apixaban	130	36
Fluticasone Propionate	Fluticasone Propionate	124	45
Tamsulosin Hcl	Tamsulosin Hcl	123	42
Jardiance	Empagliflozin	119	34
Gabapentin	Gabapentin	116	39
Hydrochlorothiazide	Hydrochlorothiazide	116	36
Allopurinol	Allopurinol	111	28
Albuterol Sulfate Hfa	Albuterol Sulfate	104	30
Ozempic	Semaglutide	104	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	99	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	89	29
Metoprolol Tartrate	Metoprolol Tartrate	89	27
Pantoprazole Sodium	Pantoprazole Sodium	83	29
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	82	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	81	26
Furosemide	Furosemide	76	27
Carvedilol	Carvedilol	73	24
Spironolactone	Spironolactone	72	22
Alprazolam	Alprazolam	59	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	59	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	18
Metformin Hcl Er	Metformin Hcl	58	15
Sertraline Hcl	Sertraline Hcl	58	18
Glipizide	Glipizide	57	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	54	suppressed
Ventolin Hfa	Albuterol Sulfate	54	17
Potassium Chloride	Potassium Chloride	53	18
Warfarin Sodium	Warfarin Sodium	50	17
Januvia	Sitagliptin Phosphate	49	16
Tramadol Hcl	Tramadol Hcl	49	15
Meloxicam	Meloxicam	45	16
Zolpidem Tartrate	Zolpidem Tartrate	43	suppressed
Diclofenac Sodium	Diclofenac Sodium	42	24
Trulicity	Dulaglutide	42	11
Atenolol	Atenolol	41	12
Trazodone Hcl	Trazodone Hcl	41	18
Ibuprofen	Ibuprofen	38	17
Famotidine	Famotidine	37	12
Finasteride	Finasteride	37	12
Pregabalin	Pregabalin	36	suppressed
Lidocaine	Lidocaine	35	18
Glipizide Er	Glipizide	34	13
Donepezil Hcl	Donepezil Hcl	33	suppressed
Montelukast Sodium	Montelukast Sodium	33	12
Triamcinolone Acetonide	Triamcinolone Acetonide	33	23
Benazepril Hcl	Benazepril Hcl	32	suppressed
Chlorthalidone	Chlorthalidone	32	suppressed
Alendronate Sodium	Alendronate Sodium	31	suppressed
Lorazepam	Lorazepam	31	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	30	11
Novolog Flexpen	Insulin Aspart	29	suppressed
Rybelsus	Semaglutide	29	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	29	12
Ezetimibe	Ezetimibe	28	suppressed
Ondansetron Odt	Ondansetron	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	21
Amiodarone Hcl	Amiodarone Hcl	25	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	24	24
Hydrocortisone	Hydrocortisone	24	12
Ketoconazole	Ketoconazole	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	20
Felodipine Er	Felodipine	22	suppressed
Cilostazol	Cilostazol	21	suppressed
Temazepam	Temazepam	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Linzess	Linaclotide	18	suppressed
Methocarbamol	Methocarbamol	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Bumetanide	Bumetanide	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Labetalol Hcl	Labetalol Hcl	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	15	15
Glimepiride	Glimepiride	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Methylprednisolone	Methylprednisolone	15	14
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Humalog	Insulin Lispro	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	14	13
Topiramate	Topiramate	14	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	13	suppressed
Colchicine	Colchicine	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Perphenazine	Perphenazine	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Azithromycin	Azithromycin	12	11
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Prednisone	Prednisone	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	11
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error